Document is current
Any future updates will be listed below
-
Authors
Liang, Xin-Quan
Han, Lin
Yan, Ting
Shao, Chun-Li
Ma, Jia-Hui
Yu, Kun-Yao
Wang, Dong-Xin https://orcid.org/0000-0002-3205-1836
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03868709 at ClinicalTrials.govDocuments that mention this clinical trial
Impact of prevention of postoperative pulmonary complications with penehyclidine inhalation on long-term outcomes in high-risk patients: follow-up of a randomized trial
https://doi.org/10.1007/s00540-026-03735-7
-
Funding
Funding for this research was provided by:
National Natural Science Foundation of China (No. 82293644)
National High Level Hospital Clinical Research Funding (No. 2022CR78)
- License Information
-
More Information
Article History
Received: 29 December 2025
Accepted: 28 March 2026
First Online: 13 April 2026
Declarations
:
: Dong-Xin Wang reports receiving research support from the National Natural Science Foundation of China (Major Program No. 82293644) and the National High Level Hospital Clinical Research Funding (High Quality Clinical Research Project of Peking University First Hospital No. 2022CR78). The study drugs were manufactured and supplied by Chengdu List Pharmaceutical Co., Ltd. (Sichuan, China). The funders had no role in the study design, data collection, data analysis, data interpretation, or writing of the report. All other authors declare that they have no conflict of interest.
: The study protocol was approved by the Biomedical Research Ethics Committee of Peking University First Hospital (2018 [213]; principal investigator D-XW; October 17, 2018). As a long-term follow-up of a randomized trial, the authors declare that they obtained written informed consent from the patients and/or volunteers in the previous study and obtained verbal consent for each follow-up. All methods were carried out in accordance with relevant guidelines and regulations.
: Not applicable.
